Compare RAY & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAY | CVKD |
|---|---|---|
| Founded | 1993 | 2022 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 6.2M |
| IPO Year | 2022 | 2022 |
| Metric | RAY | CVKD |
|---|---|---|
| Price | $2.66 | $1.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 5.1K | ★ 38.1K |
| Earning Date | 07-24-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $1.62 |
| 52 Week High | $5.99 | $14.64 |
| Indicator | RAY | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 45.47 | 31.81 |
| Support Level | $2.39 | N/A |
| Resistance Level | $3.15 | $2.17 |
| Average True Range (ATR) | 0.20 | 0.17 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 55.22 | 19.09 |
Raytech Holding Ltd is principally engaged in product designing and manufacturing of various product ranges such as Hair Care, Mens Care and Womens Care products. It has sourced and wholesaled a wide range of personal care electrical appliances, which can be broadly classified into seven categories: hair styling series, including hair dryer, hair straightener and curling iron; trimmer series, including facial shaver, nose trimmer and eyebrow trimmer; eyelash curler; nail care series and other personal care appliances such as body and facial brush, reset brush, callus remover, sonic peeling, and others.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.